Our Technology

Innovative Chemistry
Transformative Therapies

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.


Long Term

Events & Presentations

Ensysce Corporate Overview Find Out More

Events & Presentations

Special Meeting of Stockholders Find Out More

Events & Presentations

2022 Annual Meeting of Stockholders Find Out More
As the White House attempts to expand overdose treatment, Ensysce is planning to provide pain relief with overdose protection Read More
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614 Read More
Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar Read More
Ensysce Biosciences Provides Corporate Update Read More
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PHD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt

Chief Medical Officer.

Jeffrey Millard, PHD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano

Chief Development Officer